Mechanisms of Bone Destruction in Myeloma

Rebecca Silbermann, G. David Roodman

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Multiple myeloma (MM) is a plasma cell malignancy characterized by monoclonal paraprotein production. It is the second most common hematologic malignancy and has the highest incidence of bone involvement amongst malignant diseases. Up to 90% of patients with MM have evidence of osteolysis in the form of generalized osteopenia or discrete lytic lesions. Skeletal lesions in MM are distinct from bone involvement in other malignancies and are characterized by generalized increased osteoclast activity and suppressed osteoblast function with decreased new bone formation. This chapter will review the pathophysiology of myeloma bone disease and discuss current treatment strategies and novel targets for management of myeloma bone disease.

Original languageEnglish (US)
Title of host publicationOsteoporosis: Fourth Edition
PublisherElsevier Inc.
Pages1465-1478
Number of pages14
ISBN (Print)9780124158535
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Multiple Myeloma
Bone Diseases
Bone and Bones
Paraproteins
Osteolysis
Metabolic Bone Diseases
Osteoclasts
Hematologic Neoplasms
Plasma Cells
Osteoblasts
Osteogenesis
Neoplasms
Incidence
Therapeutics

Keywords

  • Bisphosphonate
  • Bone destruction
  • Multiple myeloma (MM)
  • Nuclear factor-kappaB/receptor activator
  • OBL suppression

ASJC Scopus subject areas

  • Medicine(all)
  • Dentistry(all)

Cite this

Silbermann, R., & Roodman, G. D. (2013). Mechanisms of Bone Destruction in Myeloma. In Osteoporosis: Fourth Edition (pp. 1465-1478). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-415853-5.00062-5

Mechanisms of Bone Destruction in Myeloma. / Silbermann, Rebecca; Roodman, G. David.

Osteoporosis: Fourth Edition. Elsevier Inc., 2013. p. 1465-1478.

Research output: Chapter in Book/Report/Conference proceedingChapter

Silbermann, R & Roodman, GD 2013, Mechanisms of Bone Destruction in Myeloma. in Osteoporosis: Fourth Edition. Elsevier Inc., pp. 1465-1478. https://doi.org/10.1016/B978-0-12-415853-5.00062-5
Silbermann R, Roodman GD. Mechanisms of Bone Destruction in Myeloma. In Osteoporosis: Fourth Edition. Elsevier Inc. 2013. p. 1465-1478 https://doi.org/10.1016/B978-0-12-415853-5.00062-5
Silbermann, Rebecca ; Roodman, G. David. / Mechanisms of Bone Destruction in Myeloma. Osteoporosis: Fourth Edition. Elsevier Inc., 2013. pp. 1465-1478
@inbook{0d96c0528f0042f9ba3dac66de60416e,
title = "Mechanisms of Bone Destruction in Myeloma",
abstract = "Multiple myeloma (MM) is a plasma cell malignancy characterized by monoclonal paraprotein production. It is the second most common hematologic malignancy and has the highest incidence of bone involvement amongst malignant diseases. Up to 90{\%} of patients with MM have evidence of osteolysis in the form of generalized osteopenia or discrete lytic lesions. Skeletal lesions in MM are distinct from bone involvement in other malignancies and are characterized by generalized increased osteoclast activity and suppressed osteoblast function with decreased new bone formation. This chapter will review the pathophysiology of myeloma bone disease and discuss current treatment strategies and novel targets for management of myeloma bone disease.",
keywords = "Bisphosphonate, Bone destruction, Multiple myeloma (MM), Nuclear factor-kappaB/receptor activator, OBL suppression",
author = "Rebecca Silbermann and Roodman, {G. David}",
year = "2013",
month = "6",
doi = "10.1016/B978-0-12-415853-5.00062-5",
language = "English (US)",
isbn = "9780124158535",
pages = "1465--1478",
booktitle = "Osteoporosis: Fourth Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Mechanisms of Bone Destruction in Myeloma

AU - Silbermann, Rebecca

AU - Roodman, G. David

PY - 2013/6

Y1 - 2013/6

N2 - Multiple myeloma (MM) is a plasma cell malignancy characterized by monoclonal paraprotein production. It is the second most common hematologic malignancy and has the highest incidence of bone involvement amongst malignant diseases. Up to 90% of patients with MM have evidence of osteolysis in the form of generalized osteopenia or discrete lytic lesions. Skeletal lesions in MM are distinct from bone involvement in other malignancies and are characterized by generalized increased osteoclast activity and suppressed osteoblast function with decreased new bone formation. This chapter will review the pathophysiology of myeloma bone disease and discuss current treatment strategies and novel targets for management of myeloma bone disease.

AB - Multiple myeloma (MM) is a plasma cell malignancy characterized by monoclonal paraprotein production. It is the second most common hematologic malignancy and has the highest incidence of bone involvement amongst malignant diseases. Up to 90% of patients with MM have evidence of osteolysis in the form of generalized osteopenia or discrete lytic lesions. Skeletal lesions in MM are distinct from bone involvement in other malignancies and are characterized by generalized increased osteoclast activity and suppressed osteoblast function with decreased new bone formation. This chapter will review the pathophysiology of myeloma bone disease and discuss current treatment strategies and novel targets for management of myeloma bone disease.

KW - Bisphosphonate

KW - Bone destruction

KW - Multiple myeloma (MM)

KW - Nuclear factor-kappaB/receptor activator

KW - OBL suppression

UR - http://www.scopus.com/inward/record.url?scp=84903082391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903082391&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-415853-5.00062-5

DO - 10.1016/B978-0-12-415853-5.00062-5

M3 - Chapter

AN - SCOPUS:84903082391

SN - 9780124158535

SP - 1465

EP - 1478

BT - Osteoporosis: Fourth Edition

PB - Elsevier Inc.

ER -